Eriksson UG - Search Results

1

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.

Wåhlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H. Wåhlander K, et al. Among authors: eriksson ug, eriksson h. Thromb Res. 2002 Aug 15;107(3-4):93-9. doi: 10.1016/s0049-3848(02)00259-1. Thromb Res. 2002. PMID: 12431473 Clinical Trial.

2

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Wåhlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. Wåhlander K, et al. Among authors: eriksson ug, eriksson lepkowska m. Clin Pharmacokinet. 2003;42(8):755-64. doi: 10.2165/00003088-200342080-00004. Clin Pharmacokinet. 2003. PMID: 12846596 Clinical Trial.

3

Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.

Johansson S, Wåhlander K, Larson G, Ohlsson L, Larsson M, Eriksson UG. Johansson S, et al. Among authors: eriksson ug. Blood Coagul Fibrinolysis. 2003 Oct;14(7):677-84. doi: 10.1097/00001721-200310000-00010. Blood Coagul Fibrinolysis. 2003. PMID: 14517494 Clinical Trial.

4

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.

Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wåhlander K, Eliasson A, Karlson BW, Sheth SB, Held P. Carlsson SC, et al. Among authors: eriksson ug. Thromb Res. 2005;115(1-2):9-18. doi: 10.1016/j.thromres.2004.07.001. Thromb Res. 2005. PMID: 15567447 Review. No abstract available.

5

Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.

Cullberg M, Eriksson UG, Wåhlander K, Eriksson H, Schulman S, Karlsson MO. Cullberg M, et al. Among authors: eriksson ug, eriksson h. Clin Pharmacol Ther. 2005 Apr;77(4):279-90. doi: 10.1016/j.clpt.2004.11.001. Clin Pharmacol Ther. 2005. PMID: 15903126 Clinical Trial.

6

Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.

Wåhlander K, Eriksson-Lepkowska M, Nyström P, Eriksson UG, Sarich TC, Badimon JJ, Kalies I, Elg M, Bylock A. Wåhlander K, et al. Among authors: eriksson ug, eriksson lepkowska m. Thromb Haemost. 2006 Mar;95(3):447-53. doi: 10.1160/TH05-10-0664. Thromb Haemost. 2006. PMID: 16525572 Clinical Trial.

7

Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.

Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsén M. Eriksson H, et al. Among authors: eriksson ug. Thromb Haemost. 1999 Mar;81(3):358-63. Thromb Haemost. 1999. PMID: 10102460 Clinical Trial.

8

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.

Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wåhlander K, Gustafsson D, Badimon JJ. Sarich TC, et al. Among authors: eriksson ug, eriksson lepkowska m. J Thromb Haemost. 2003 May;1(5):999-1004. doi: 10.1046/j.1538-7836.2003.00201.x. J Thromb Haemost. 2003. PMID: 12871368 Free article. Clinical Trial.

9

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.

Lip GY, Rasmussen LH, Olsson SB, Zetterstrand S, Stahre C, Bylock A, Aunes-Jansson M, Eriksson U, Wåhlander K; Steering Committee. Lip GY, et al. Thromb Res. 2011 Feb;127(2):91-9. doi: 10.1016/j.thromres.2010.11.012. Epub 2010 Dec 18. Thromb Res. 2011. PMID: 21172721 Clinical Trial.

10

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.

Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, Gustafsson D. Eriksson UG, et al. Drug Metab Dispos. 2003 Mar;31(3):294-305. doi: 10.1124/dmd.31.3.294. Drug Metab Dispos. 2003. PMID: 12584156

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters